Rheumatoid Arthritis (RA) is a chronic systemic inflammatory autoimmune disease characterized by persistent synovial inflammation. The degrees of severity range from mild, limited disease to severe disease associated with progressive joint destruction, significantly compromised quality of life and reduced survival. Substantial complications include excess cardiovascular risk, dyslipidemia and increased risk of infections. The persistent inflammation of RA leads to progressive joint destruction with cartilage loss, erosive damage to joints with resulting functional impairment.
Management of RA has improved considerably in recent years. In addition to reduction of symptoms, improvement of physical function and decreased joint damage and clinical remission are now considered achievable goals. Therefore, the current recommended target for the treatment of RA is remission. The goals of RA management are to improve signs and symptoms, prevent loss of function and minimize structural joint damage, which can occur within the first 3-6 months of disease onset.
Albuquerque Clinical Trials is conducting Rheumatoid Arthritis research studies to further the advancement of future treatment for the disease. Each study has different enrollment criteria, however all study procedures, lab work, doctor’s exams and medications are covered at no cost to the patients, and a stipend for time and travel may be available.
If you would like more information about our different trials or would like to see if you qualify please sign up using our Participant Sign Up Form.